BioMerieux SA
BIM
Company Profile
Business description
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (34% of 2023 sales), microbiology (39%), immunoassays (10%), and industrial applications (about 17%). The Amercas account for the largest portion of the firm's revenue (45%), followed by Europe, the Middle East, and Africa (31%), and Asia-Pacific (16%). BioMérieux is headquartered in Marcy-l'Etoile, France.
Contact
Marcy l’Etoile
Lyon69280
FRAT: +33 478872000
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
14,754
Stocks News & Analysis
stocks
Here’s how to value a share
Our best resources to help investors determine the value of a share.
stocks
How to avoid dividend disaster
Thinking about common reasons a company might stop paying a dividend can help income investors avoid disappointment.
stocks
GyG punished by market after solid earnings
Although Guzman y Gomez had solid earnings, it failed to meet lofty market expectations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,256.80 | 54.50 | -0.59% |
| CAC 40 | 7,969.69 | 31.40 | 0.40% |
| DAX 40 | 24,363.09 | 69.75 | 0.29% |
| Dow JONES (US) | 45,631.74 | 846.24 | 1.89% |
| FTSE 100 | 9,321.40 | 12.20 | 0.13% |
| HKSE | 25,840.06 | 500.92 | 1.98% |
| NASDAQ | 21,496.54 | 396.22 | 1.88% |
| Nikkei 225 | 42,922.04 | 288.75 | 0.68% |
| NZX 50 Index | 13,102.17 | 59.41 | 0.46% |
| S&P 500 | 6,466.91 | 96.74 | 1.52% |
| S&P/ASX 200 | 8,984.40 | 59.70 | -0.66% |
| SSE Composite Index | 3,866.89 | 41.13 | 1.08% |